What question did this study set out to answer?

To evaluate the anti-metastatic efficacy and underlying molecular signaling mechanisms of the novel quinazoline derivative MJ-56 in HT29 human colorectal cancer cells.

May 16, 2013International Journal of OncologyOpen Access

Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells

View Full Paper

Ask AI

Bookmark

Authors

HCHui‐Jye ChenChina Medical University YJYilin JiangHarbin University of Science and Technology CLChung-Ming LinMing Chuan University

Discussion

Member takes

Implication

In vitro study demonstrates reduced migration and invasion in HT29 colorectal cancer cells via dual EGFR and c-Met inhibition, highlighting MJ-56 as a candidate antimetastatic therapy.

Key Points

To evaluate the anti-metastatic efficacy and underlying molecular signaling mechanisms of the novel quinazoline derivative MJ-56 in HT29 human colorectal cancer cells.
Assessed HT29 cell migration and invasion across concentrations using wound-healing and Matrigel-coated transwell assays.
Measured protein expression and enzymatic activity of matrix metalloproteinases (MMP-2, -7, -9, -10) and tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2).
Evaluated phosphorylation states of EGFR, c-Met, ERK/MAPK, PI3K/AKT/mTOR, NF-κB, and translation initiation factors (eIF-4B, eIF-4E, eIF-4G, S6 ribosomal protein).
MJ-56 concentration-dependently reduced HT29 cell migration and invasion, accompanied by decreased expression of MMP-2, -7, -9, and -10, reduced enzymatic activities of MMP-2 and -9, and increased TIMP-1 and TIMP-2 levels.
Treatment attenuated the activation of EGFR, c-Met, ERK-mediated MAPK, and PI3K/AKT/mTOR signaling pathways, leading to dephosphorylation of translation initiation factors and impaired NF-κB-mediated MMP transcription.

Cite This Study

Chen et al. (2013) studied this question.

synapsesocial.com/papers/6aa64d804dd50f8a0764c22d https://doi.org/10.3892/ijo.2013.1941

View Full Paper

Ask AI

Bookmark

Implication

In vitro study demonstrates reduced migration and invasion in HT29 colorectal cancer cells via dual EGFR and c-Met inhibition, highlighting MJ-56 as a candidate antimetastatic therapy.

Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider